PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
43.43%
EBIT growth of 43.43% while Biotechnology median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
-14.45%
Negative operating income growth while Biotechnology median is -1.48%. Seth Klarman would check if structural or cyclical issues are at play.
43.33%
Positive net income growth while Biotechnology median is negative. Peter Lynch would view this as a notable competitive advantage.
43.35%
EPS growth of 43.35% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
43.35%
Diluted EPS growth of 43.35% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.17%
Negative OCF growth while Biotechnology median is -5.90%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-15.15%
Negative FCF growth while Biotechnology median is -3.80%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-167027.54%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-35848.35%
Negative 5Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-39776.52%
Negative 3Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-711192.96%
Negative 10Y net income/share CAGR vs. Biotechnology median of 1.09%. Seth Klarman might see a fundamental problem if peers maintain growth.
-12332.31%
Negative 5Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-13057.95%
Negative 3Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
90012.37%
Equity/share CAGR of 90012.37% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
5373.91%
5Y equity/share CAGR of 5373.91% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
7310.97%
3Y equity/share CAGR of 7310.97% while Biotechnology median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
164.96%
Asset growth of 164.96% while Biotechnology median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
955.36%
Positive BV/share change while Biotechnology median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
-33.08%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
0.44%
R&D growth of 0.44% while Biotechnology median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
34.62%
SG&A growth of 34.62% while Biotechnology median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.